rhbmp2 solution  (Medtronic inc)

Journal: Biomaterials Research

Article Title: Regeneration of a Rabbit Segmental Defect with a New Bone Therapy: Autologous Blood Coagulum with Bone Morphogenetic Protein 6 and Synthetic Ceramics

doi: 10.34133/bmr.0140

Figure Lengend Snippet: Experimental groups, implant preparation, surgical technique, and outcome for the macerated specimen of a rabbit forearm showing a regenerated ulnar segmental defect. Implant preparation of (1) Infuse (recombinant human bone morphogenetic protein 2 [rhBMP2]/absorbable collagen sponge [ACS]), (2) Osteogrow (recombinant human bone morphogenetic protein 6 [rhBMP6]/autologous blood coagulum [ABC]), and (3) Osteogrow-C containing tricalcium phosphate (TCP) or biphasic calcium phosphate (BCP). (4) Schematic preview of a rabbit critical size defect (CSD) model with a defect of 15 mm stabilized with a metal plate. (5) Macerated specimen of the rabbit forearm and regenerated ulnar defect using Osteogrow-C containing BCP (orange rectangle) and screw holes from the removed plate (green rectangle). CRM, compressive resistant matrix.

Article Snippet: Implants composed of rhBMP2/ACS (group D) were prepared by uniform application of rhBMP2 solution (100 μg; Medtronic BioPharma B.V., The Netherlands) to ACS (Integra LifeSciences Corporation, NJ, USA) with dimensions of 12.7 mm × 25.4 mm × 7 mm (Fig. ).

Techniques: Recombinant

Journal: Biomaterials Research

Article Title: Regeneration of a Rabbit Segmental Defect with a New Bone Therapy: Autologous Blood Coagulum with Bone Morphogenetic Protein 6 and Synthetic Ceramics

doi: 10.34133/bmr.0140

Figure Lengend Snippet: Ulnar segmental defect treated with rhBMP2/ACS (Infuse) and rhBMP6/ABC (Osteogrow). (A) Three-dimensional reconstructions and (B) microCT sections (sagittal plane) of an ulnar segmental defect treated with rhBMP2/ACS and rhBMP6/ABC. (C) MicroCT analysis of regenerated bone on the segmental defect site showing bone volume (mm 3 ) and trabecular parameters including thickness (mm), number (1/mm), and separation (mm). Histological sections of whole specimens and region of interest (ROI) presenting a place of defect (orange rectangle) treated with (D) rhBMP2/ACS and (E) rhBMP6/ABC with accompanying images on higher magnifications (D and E (1 and 2)). Sections were stained by modified Goldner stain (D 1 and E 1) where the newly formed bone is green and by Von Kossa stain (D 2 and E 2) with bone in black. Yellow arrows indicate adipocytic bone marrow. Scale bars are shown in the lower right corners of D (1 and 2) and E (1 and 2).

Article Snippet: Implants composed of rhBMP2/ACS (group D) were prepared by uniform application of rhBMP2 solution (100 μg; Medtronic BioPharma B.V., The Netherlands) to ACS (Integra LifeSciences Corporation, NJ, USA) with dimensions of 12.7 mm × 25.4 mm × 7 mm (Fig. ).

Techniques: Staining, Modification

Journal: Biomaterials Research

Article Title: Regeneration of a Rabbit Segmental Defect with a New Bone Therapy: Autologous Blood Coagulum with Bone Morphogenetic Protein 6 and Synthetic Ceramics

doi: 10.34133/bmr.0140

Figure Lengend Snippet: MicroCT analyses of regenerated bone 17 weeks after treatment on the sites of segmental defects treated with 4 osteoinductive formulations, namely, rhBMP2/ACS (Infuse), rhBMP6/ABC (Osteogrow), and 2 formulations of Osteogrow-C. (A) Bone volume (mm 3 ) of newly formed bone at the defect site among tested formulations. (B) Measurements of cortical thickness among tested formulations. (C) Residual ceramics volume (mm 3 ) among tested Osteogrow-C formulations. (D) Segmentation of ulnar bone (gray) and ceramic particles in green (TCP) and blue colors (BCP) showing the different resorption rates of ceramic particles. (E) Trabecular parameters, namely, thickness (mm), number (1/mm), and separation (mm), among experimental groups. The number of analyzed specimens was 5 or 4 per group. All P values below 0.05 were considered significant and are marked with asterisks: * P ≤ 0.05, ** P ≤ 0.01, and *** P ≤ 0.001.

Article Snippet: Implants composed of rhBMP2/ACS (group D) were prepared by uniform application of rhBMP2 solution (100 μg; Medtronic BioPharma B.V., The Netherlands) to ACS (Integra LifeSciences Corporation, NJ, USA) with dimensions of 12.7 mm × 25.4 mm × 7 mm (Fig. ).

Techniques: